MIRA Pharmaceuticals closed at $0.56 on Nov 4, up 8.34%, 67.0% below its 52-week closing high. Volume of 79.7K shares was 0.53× its 20-day average (below normal).
Split-adjusted performance: -21.2% over one month, -43.9% over six months, -67.0% over one year.
Short interest was 349.7K shares at the Oct 15 settlement, down 14.5% from the prior report (1.2% of float, 2.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MIRAMIRA Pharmaceuticals | $0.5610 | +8.34% | −43.9% | — | — | — | $23.6M | |
| CRVOCervoMed | $1.56 | +0.65% | −59.3% | −100.0% | — | — | $23.6M | Compare |
| SHPHShuttle Pharmaceuticals Holdings | $5.21 | +1.17% | −33.2% | — | — | — | $24.8M | Compare |
| CPHIChina Pharma Holdings | $0.5875 | −3.56% | +11.4% | −7.5% | −153.8% | — | $25.3M | Compare |
| CELUCelularity | $0.8088 | −1.02% | −13.0% | −5.3% | 10.1% | — | $26.2M | Compare |
| ATOSAtossa Therapeutics | $2.12 | −9.01% | −63.4% | — | — | — | $21.2M | Compare |
| TXMDTherapeuticsMD | $1.82 | +2.25% | −10.3% | −8.7% | 17.8% | — | $21.1M | Compare |
| MCRBSeres Therapeutics | $2.09 | +6.63% | −73.9% | — | 622.4% | — | $21.0M | Compare |
| EDSAEdesa Biotech | $2.17 | −4.82% | −85.5% | — | — | — | $20.9M | Compare |
No recent articles focused on MIRA Pharmaceuticals.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
